176 related articles for article (PubMed ID: 38074953)
41. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study.
Rathish B; Wilson A; Warrier A; Prakash S; Babu R; Joy S
Cureus; 2021 Feb; 13(2):e13081. PubMed ID: 33680621
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae.
Pérez-Nadales E; Fernández-Ruiz M; Natera AM; Gutiérrez-Gutiérrez B; Mularoni A; Russelli G; Pierrotti LC; Pinheiro Freire M; Falcone M; Tiseo G; Tumbarello M; Raffaelli F; Abdala E; Bodro M; Gervasi E; Fariñas MC; Seminari EM; Castón JJ; Marín-Sanz JA; Gálvez-Soto V; Rana MM; Loeches B; Martín-Dávila P; Pascual Á; Rodríguez-Baño J; Aguado JM; Martínez-Martínez L; Torre-Cisneros J;
Am J Transplant; 2023 Jul; 23(7):1022-1034. PubMed ID: 37028515
[TBL] [Abstract][Full Text] [Related]
43. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
44. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by
Guimarães T; Nouér SA; Martins RCR; Perdigão Neto LV; Martins WMBS; Narciso Barbosa AC; Ferreira ALP; Costa SF; Gales AC
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358592
[TBL] [Abstract][Full Text] [Related]
45. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.
Lima O; Sousa A; Longueira-Suárez R; Filgueira A; Taboada-Martínez C; Portela-Pino C; Nodar A; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1173-1182. PubMed ID: 35939239
[TBL] [Abstract][Full Text] [Related]
46. Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials.
Che H; Wang R; Wang J; Cai Y
Int J Antimicrob Agents; 2019 Dec; 54(6):809-813. PubMed ID: 31533075
[TBL] [Abstract][Full Text] [Related]
47. Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant
Zhang L; Ma Y; Zhao C; Zhao S; Zhao L; Yang Y; Wang Y; Meng H; Sun J
Infect Drug Resist; 2024; 17():239-248. PubMed ID: 38293316
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
49. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
[TBL] [Abstract][Full Text] [Related]
50. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
51. Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910899
[TBL] [Abstract][Full Text] [Related]
52. Clinical Outcome of Patients on Ceftazidime-Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae.
Nagvekar V; Shah A; Unadkat VP; Chavan A; Kohli R; Hodgar S; Ashpalia A; Patil N; Kamble R
Indian J Crit Care Med; 2021 Jul; 25(7):780-784. PubMed ID: 34316172
[TBL] [Abstract][Full Text] [Related]
53. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
54. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
56. Author Response.
Vijayakumar M; Selvam V; Renuka MK; Rajagopalan RE
Indian J Crit Care Med; 2024 May; 28(5):515. PubMed ID: 38738190
[No Abstract] [Full Text] [Related]
57. Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant
Chen J; Liang Q; Ding S; Xu Y; Hu Y; Chen J; Huang M
Infect Drug Resist; 2023; 16():2237-2246. PubMed ID: 37090036
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant
Zhang F; Zhong J; Ding H; Liao G
Infect Drug Resist; 2021; 14():5165-5174. PubMed ID: 34908850
[TBL] [Abstract][Full Text] [Related]
59. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.
Tumbarello M; Losito AR; Giamarellou H
Curr Opin Infect Dis; 2018 Dec; 31(6):566-577. PubMed ID: 30379732
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
Onorato L; Di Caprio G; Signoriello S; Coppola N
Int J Antimicrob Agents; 2019 Dec; 54(6):735-740. PubMed ID: 31479738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
